HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Cipla Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Cipla Intelligence Report

Generated from 9 signals · 3 evidence sources

Type

Company Intelligence Report

Generated

Aug 4, 2026

Confidence

Moderate Confidence · 69%

Evidence

49 items

Sources

11

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Cipla maintains an active intelligence profile across Hematology, Multiple Myeloma, Respiratory, Bronchodilator, Psychiatry. 9 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 69% across 3 tracked sources. Highest-priority development: FDA TA — CANAGLIFLOZIN (ORIG). Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Cipla; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA TA — CANAGLIFLOZIN (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    FDA AP — BUPROPION HYDROCHLORIDE (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    FDA AP — NEURACEQ (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    FDA AP — CHILDREN'S MOTRIN (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA AP — REVLIMID (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA AP — MORPHINE SULFATE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    FDA AP — MORPHINE SULFATE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    FDA AP — MORPHINE SULFATE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA AP — ALBUTEROL SULFATE (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA AP — ALBUTEROL SULFATE (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    Drug Trials Snapshots: YARTEMLEA

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 464 with buyer quality 6 (Emerging). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA TA — CANAGLIFLOZIN (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BUPROPION HYDROCHLORIDE (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — NEURACEQ (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — CHILDREN'S MOTRIN (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — REVLIMID (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MORPHINE SULFATE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MORPHINE SULFATE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MORPHINE SULFATE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ALBUTEROL SULFATE (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ALBUTEROL SULFATE (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Drug Trials Snapshots: YARTEMLEA

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Opportunities for patients and the public to be involved in the work of the MHRA

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • Ongoing | Cancer Accelerated Approvals

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — LENALIDOMIDE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — LENALIDOMIDE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Approves Albuterol Sulfate ANDA219409 from Cipla

    Respiratory · Bronchodilator

  • Phase II Trial of Pramipexole vs Escitalopram for MDD in HIV Patients

    Psychiatry · Major Depressive Disorder

  • Cipla's Lenalidomide ANDA210435 Receives Abbreviated Approval from FDA

    Oncology · Multiple Myeloma

  • Cipla's ANDA214209 for Sumatriptan Receives Abbreviated Approval from FDA

    Neurology · Migraine

  • Cipla's Lenalidomide ANDA213165 Receives AP Status from FDA

    Hematology · Multiple Myeloma

  • Cipla's Albuterol Sulfate ANDA219409 Receives FDA Approval Status

    Respiratory · Bronchodilator

  • Cipla's Lenalidomide ANDA213165 Receives AP Status from FDA

    Oncology · Small Molecule

  • Cipla's Albuterol Sulfate ANDA219409 Receives AP Status from FDA

    Respiratory · Bronchodilator

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.